CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Zhejiang Xinguang Pharmaceutical Co Ltd Company Snapshot
Zhejiang Xinguang Pharmaceutical Co Ltd operates in the Pharmaceutical preparations sector. In addition to historical fundamental analyses, the complete report available to purchase compares Zhejiang Xinguang Pharmaceutical Co Ltd with three other companies in this sector in CHINA : Shenzhen Chipscreen Biosciences Co Ltd (2020 sales of 269.47 million Chinese Renmimbi [US$42.21 million] of which 100% was Chidamide), Jilin Zixin Pharmaceutical Industrial Co Ltd (285.54 million Chinese Renmimbi [US$44.73 million] of which 95% was Chinese patent medicines), and Tus Pharmaceutical Group Co Ltd (275.09 million Chinese Renmimbi [US$43.09 million] of which 92% was Chinese medicine health care production ).

Sales Analysis. During the second quarter of 2021, sales at Zhejiang Xinguang Pharmaceutical Co Ltd totalled 62.58 million Chinese Renmimbi. This is an increase of 9.0% from the 57.43 million Chinese Renmimbi in sales at the company during the second quarter of 2020. During the first two quarters of 2021, sales totalled 159.50 million Chinese Renmimbi, which is 24.4% higher than through the first two quarters of 2020. There appears to be at least some degree of seasonality in the sales at Zhejiang Xinguang Pharmaceutical Co Ltd: during 5 of the previous 6 years, sales were highest during the first quarter. The exception to this was during 2020, when the third quarter was the best quarter, accounting for 30% of sales (during that same year, the first quarter accounted for 25% of sales). Zhejiang Xinguang Pharmaceutical Co Ltd reported sales of 283.08 million Chinese Renmimbi (US$44.34 million) for the year ending December of 2020. This represents a decrease of 2.8% versus 2019, when the company's sales were 291.26 million Chinese Renmimbi. The sales level in 2020 was fairly close to the level five years ago: in 2015, Zhejiang Xinguang Pharmaceutical Co Ltd had sales of 311.44 million Chinese Renmimbi. Contributing to the drop in overall sales was the 13.2% decline in Shenjin Dan Capsule, from 31.51 million Chinese Renmimbi to 27.36 million Chinese Renmimbi. There were also decreases in sales in Huangqi Shengmai Drink (down 3.9% to 215.92 million Chinese Renmimbi) . However, these declines were partially offset by the increase in sales of American Ginseng Oral Solution (up 16.3% to 32.09 million Chinese Renmimbi) and Other Products (up 2.3% to 7.59 million Chinese Renmimbi) and Other Operations (up 4.6% to 123,470.95 Chinese Renmimbi) .
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Zhejiang Xinguang Pharmaceutical Co Ltd
  Stock Performance Chart for Zhejiang Xinguang Pharmaceutical Co Ltd
 
  Stock Data: Recent Stock Performance:
  Current Price (10/22/2021): 15.22
(Figures in Chinese Renmimbi)
1 Week -3.6%   13 Weeks -7.9%  
4 Weeks -15.1%   52 Weeks -39.7%  
 
Zhejiang Xinguang Pharmaceutical Co Ltd Key Data:
  Ticker: 300519 Country: China
  Exchanges: SZN Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Pharmaceutical Preparations
  2020 Sales 283,080,271
(Year Ending Jan 2021).
Employees: 321
  Currency: Chinese Renmimbi Market Cap: 2,435,200,000
  Fiscal Yr Ends: December Shares Outstanding: 160,000,000
  Share Type: A Gu Closely Held Shares:
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.